Biospecimens and Patient Registry

生物样本和患者登记

• 批准号: 10705037
• 负责人: MARK E SHERMAN
• 金额: $ 18.66万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10705037
• 关键词: Animal Model; Antibodies; Archives; Ascites; Back; Benign; Bioinformatics; Biological Assay; Biological Markers; Biometry; Biopsy; Blood; Cancer Center; Cancer Patient; Cancer Research Project; Cancer-Predisposing Gene; Carcinoma; Cell Line; Cells; Classification; Clinic; Clinical; Clinical Data; Clinical Trials; Collaborations; Collection; Communities; Confidentiality of Patient Information; Consent; Cytogenetics; DNA; Data; Data Analyses; Data Set; Databases; Dedications; Dendritic Cell Vaccine; Detection; Development; Ethics; Evaluation; Fluorescent in Situ Hybridization; Freezing; Funding; Future; Generations; Genes; Genomics; Goals; Grant; Histology; Immunohistochemistry; In Situ Hybridization; Informed Consent; Institution; Ions; Link; MSLN gene; Maintenance; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of ovary; Mammalian Oviducts; Mayo Clinic Cancer Center; Medical Records; Morphology; Natural Killer Cells; Neoplasm Circulating Cells; Normal tissue morphology; Operative Surgical Procedures; Organoids; Outcome; Ovarian; Paraffin; Paraffin Embedding; Pathologic; Pathology; Patient Recruitments; Patients; Performance; Peripheral Blood Mononuclear Cell; Peritoneal; Phase; Phase II Clinical Trials; Phase Ib Clinical Trial; Play; Pre-Clinical Model; Prevention; Proteins; Quality Control; Questionnaires; RAD51C gene; RNA; Records; Research; Research Personnel; Research Project Grants; Research Support; Resource Sharing; Resources; Risk; Risk Assessment; Risk Factors; Role; Sampling; Serum; Services; Site; Slide; Specimen; Stains; Standardization; Surveys; TOP1 gene; Time; Tissue Banks; Tissue Embedding; Tissue Microarray; Tissues; Translational Research; Tumor Tissue; Woman; Writing; Xenograft procedure; anticancer research; blood product; brca gene; cancer therapy; chimeric antigen receptor; cohort; data management; design; digital imaging; follow-up; high risk; histological slides; immune cell infiltrate; improved; member; novel; ovarian neoplasm; participant enrollment; patient derived xenograft model; patient registry; peritoneal cancer; programs; prospective; recruit; sound; stem cells; time use; tissue registry; tumor; vaccine trial

ABSTRACT – BIOSPECIMENS AND PATIENT REGISTRY CORE (CORE B) The goal of the Biospecimens and Patient Registry Core (Core B) is to provide the Mayo Clinic SPORE in Ovarian Cancer investigators with high quality patient clinical data, DNA, RNA, blood products, and tissues (normal and malignant) from consented patients with ovarian, fallopian tube, or primary peritoneal carcinoma and suitable controls, and to make these resources available for future studies. The Mayo Clinic has a strong tradition of ethically sound support of research that links tissue acquisition and patient data records. Paraffin embedded tissues, histological slides, and associated patient charts from surgeries performed since the first decade of the 1900's are maintained in Mayo’s Tissue Registry and the Mayo Archives. Core B interacts with i) the Pathology Research Core of the Mayo Clinic Cancer Center, which provides expertise, collaborative support, and service for immunohistochemistry, in situ hybridization, tissue microarray construction, and digital imaging; ii) the Biospecimens Accessioning and Processing Core, which is the primary site of accessioning and standardized processing of blood and frozen tissue collected explicitly for research from all three Mayo sites; and iii) the Cytogenetics Core, which has expertise in establishing, validating, and scoring fluorescence in situ hybridization (FISH) studies. Core B is integrated with these existing tissue-oriented Cancer Center shared resources and other scientific Cores of this SPORE to provide a coordinated, centralized, dedicated program for standardized collection, accessioning, processing, morphologic classification, and genomic annotation of biospecimens so that these can be studied in the context of patient data from fully consented patients. Thorough clinical annotation is required to maximize the potential use of tissue specimens in translational research; therefore, risk factor questionnaires, clinical records, and pathology review are incorporated into the Core. Research services, including pathologic review of tumor histology, tumor sectioning and quality control, blood processing, construction of tissue microarrays (TMAs), immunohistochemistry (IHC), and FISH, will be provided as needed to SPORE investigators. Core B is closely coordinated with the Biostatistics and Bioinformatics Core (Core C) to provide seamless linkage of clinical annotation with research specimens for data management and analyses. In Years 6-10 of Mayo Clinic SPORE in Ovarian Cancer funding, Core B distributed 4326 ovarian tumor tissues, 511 TMA slides, and 3628 germline DNA samples. In addition, Core B undertook a systematic evaluation of common ovarian cancer susceptibility genes in all stored cancer specimens and successfully collaborated with a stem cell biologist, new to ovarian cancer research, to generate a novel biospecimen—benign Fallopian tube organoids from women at average risk and high risk (BRCA1/2, RAD51C, and other carriers) of ovarian cancer. Under the direction of the Administrative Core, the Biospecimens and Patient Registry Core will continue to make biospecimens collected for this SPORE available to SPORE investigators and the ovarian cancer research community at large in order to stimulate translational research with the goal of reducing the burden of ovarian cancer.

摘要-生物标本和患者登记表核心（核心B） 生物样本和患者登记核心（核心B）的目标是为马约诊所提供 卵巢癌研究人员提供高质量的患者临床数据、DNA、RNA、血液制品和组织 （正常和恶性）来自知情同意的卵巢癌、输卵管癌或原发性腹膜癌患者 和适当的控制，并使这些资源可用于未来的研究。马约诊所有一个强大的 传统的道德健全的研究，连接组织采集和病人的数据记录支持。石蜡 自第一次手术以来进行的手术的包埋组织、组织学切片和相关患者图表 1900年代的10年记录保存在马约组织登记处和马约档案馆。核心B与 i）马约诊所癌症中心的病理学研究中心，提供专业知识、合作和培训， 免疫组织化学、原位杂交、组织微阵列构建和数字化技术支持和服务 成像; ii）生物标本收集和处理中心，这是主要的登记地点 并对从三个马约医院收集的明确用于研究的血液和冷冻组织进行标准化处理 研究中心;以及iii）细胞遗传学核心，其具有建立、验证和评分荧光的专业知识 原位杂交（FISH）研究。核心B与这些现有的面向组织的癌症中心整合 共享资源和其他科学核心，以提供一个协调的，集中的，专用的 标准化收集、登记、加工、形态分类和基因组学程序 生物标本注释，以便在完全知情同意的患者数据背景下进行研究 患者需要全面的临床注释，以最大限度地利用组织标本的潜在用途， 转化研究;因此，风险因素问卷，临床记录和病理学审查是 融入核心。研究服务，包括肿瘤组织学的病理审查，肿瘤切片 和质量控制，血液处理，组织微阵列（TMAs）的构建，免疫组织化学（IHC）， 和FISH，将根据需要提供给SPORE研究者。核心B与 生物统计学和生物信息学核心（核心C）提供临床注释与研究的无缝链接 用于数据管理和分析的样本。在马约诊所卵巢癌孢子6-10年 核心B分发了4326个卵巢肿瘤组织、511个TMA载玻片和3628个生殖系DNA样本。在 此外，Core B对所有储存的卵巢癌易感基因进行了系统评价。 癌症标本，并成功地与干细胞生物学家合作，新的卵巢癌研究， 从处于平均风险和高风险的女性中产生一种新的生物素-良性输卵管类器官 （BRCA 1/2，RAD 51 C和其他携带者）卵巢癌。在行政核心的指导下， 生物标本和患者登记中心将继续为本次SPORE采集生物标本 提供给SPORE研究人员和卵巢癌研究社区，以刺激 转化研究的目的是减少卵巢癌的负担。